Skip to main content
. 2024 Apr 2;44(3):468–477. doi: 10.19852/j.cnki.jtcm.20240402.001

Figure 4. Expression of factors associated with the Pink1-Parkin pathway.

Figure 4

A: double immunofluorescence staining for Pink1 and Parkin (× 400); A-1A4: CON group; A5-A8: KOA group; A9-A12: Acu group; A1, A5, A9: DAPI staining; A2, A6, A10: Pink1 staining; A3, A7, A11: Parkin staining; A4, A8, A12: merge of Pink1 and Parkin staining; B: Pink1, Parkin, LC3Ⅱ/Ⅰ, TOM20 and TIM23 expression was detected by Western blot analyses. C: colocalization coefficient; D: mRNA expression of Pink1; E: mRNA expression of Parkin; F: Western blotting analysis of Pink1 expression; G: Western blotting analysis of Parkin expression; H: Western blotting analysis of LC3Ⅱ/Ⅰ expression; I: Western blotting analysis of TOM20 expression; J: Western blotting analysis of TIM23 expression. CON group: no modeling or no intervention; KOA group: 6 weeks of modeling followed by no intervention; Acu group: 6 weeks of modeling followed by acupotomy intervention for 4 weeks. PCC: Pearson's correlation coefficient; Pink1: PTEN-induced putative kinase 1; LC3Ⅱ/Ⅰ: microtubule-associated protein-1 light chain-3Ⅱ/Ⅰ; TOM20: translocase of the outer membrane 20; TIM23: translocase of the inner membrane 23; CON: control; KOA: knee osteoarthritis; Acu: acupotomy; DAPI: 4', 6-diamidino-2-phenylindole; PTEN: phosphatase and Tensin Homolog. The data were presented as the mean ± standard deviation (n = 6). aP < 0.01 and dP < 0.01 compared with the control group; bP < 0.01 and cP < 0.05, compared with the KOA group.